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Abstract
Background: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the most common presentation
of a disorder of sex development (DSD) in genetic females. A report of prenatal growth retardation in cases of 46,
XY DSD, coupled with observations of below-optimal final height in both males and females with congenital
adrenal hyperplasia due to 21-hydroxylase deficiency, prompted us to investigate prenatal growth in the latter
group. Additionally, because girls with congenital adrenal hyperplasia are exposed to increased levels of androgens
in the absence of a male sex-chromosome complement, the presence or absence of typical sex differences in
growth of newborns would support or refute a hormonal explanation for these differences.
Methods: In total, 105 newborns with congenital adrenal hyperplasia were identified in our database. Gestational
age (weeks), birth weight (kg), birth length (cm) and parental heights (cm) were obtained. Mid-parental height was
considered in the analyses.
Results: Mean birth weight percentile for congenital adrenal hyperplasia was 49.26%, indicating no evidence of a
difference in birth weight from the expected standard population median of 50th percentile (P > 0.05). The
expected sex difference in favor of heavier males was not seen (P > 0.05). Of the 105 subjects, 44 (27%; 34 females,
10 males) had birth length and gestational age recorded in their medical chart. Mean birth length for this
subgroup was 50.90 cm (63rd percentile), which differed from the expected standard population median of 50th
percentile (P = 0.0082). The expected sex difference in favor of longer males was also not seen (P > 0.05).
Conclusion: The prenatal growth retardation patterns reported in cases of 46,XY disorders of sex development do
not generalize to people with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Sex differences in
body weight and length typically seen in young infants were not seen in the subjects who participated in this
study. We speculate that these differences were ameliorated in this study because of increased levels of prenatal
androgens experienced by the females infants.
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Several reports have suggested an association between
low birth weight and atypical development of the male
reproductive system. For example, low birth weight is
more common in newborns with isolated hypospadias
[1-9] and in genetic males with a disorder of sex devel-
opment (DSD) [10], particularly when the DSD is idio-
pathic in nature [11-14]. Birth weight and length in
humans are sexually dimorphic traits; healthy male new-
borns weigh more and are longer than their female
counterparts [7,15]. Male newborns also have a greater
head circumference and less body fat than females, as
indicated by decreased skin-fold thickness and whole-
body plethysmography [16]. Together, these observa-
tions point to the possibility that lower levels of andro-
g e np r o d u c t i o no ra c t i o nin utero that would be
expected for a male contributes not only to undermas-
culinization of the male reproductive system, but also to
decreased anthropometric measures in newborns [7].
Low birth weight is of concern, independently of its
relationship with atypical reproductive development,
because of the association with development of meta-
bolic, endocrine and cardiovascular diseases later in life
[17]. Furthermore, some newborns who are born small
fail to achieve catch-up growth as they develop.
Congenital adrenal hyperplasia (CAH) due to 21-hydro-
xylase deficiency (21-OH) is the commonest cause of DSD
in 46,XX individuals. Females with this condition are
exposed during early development to levels of androgens
that can be similar to the atypically low levels of androgens
experienced by some genetic males with DSD. Further-
more, both under- and over-treatment of CAH with glu-
cocorticoids results in a final adult height that is shorter
than that predicted from mean parental height (MPH)
[18]. A better understanding of crucial periods of growth,
including the prenatal period, should prove beneficial in
efforts to optimize final heights in people with CAH [19].
To our knowledge, only three published studies have
analyzed prenatal growth in newborns with CAH due to
21-hydroxylase (21-OH) deficiency. The first study
reported normal birth weight [20], and the second
reported an increase in birth weight in affected girls but
not boys [21]. These data indicate that, unlike cases of
46,XY DSD, ‘small for gestational age’ cannot be gener-
alized to the most common presentation of 46,XX DSD.
However, neither study controlled for the possible con-
founding effects of parental height on birth weight. The
third study measured linear growth in boys and girls
with classic CAH during the first 3 years of life. and
reported that birth length was above average for affected
children; however, neither sex differences nor body mass
data were considered in thst study [22].
The goal of the present study was to retrospectively
evaluate birth weight and length in newborns with CAH
due to 21-OH deficiency whereas controlling for the
influence of parental height. Furthermore, because
female newborns with CAH due to 21-OH deficiency
are exposed to increased levels of androgens before
treatment in the absence of a male sex-chromosome
complement, their growth patterns allow us to discrimi-
nate between hormonal versus genetic influences in the
context of sexually dimorphic anthropometric measures.
Methods
The study was approved by the institutional review
boards of the University of Oklahoma Health Sciences
Center and the Johns Hopkins School of Medicine,
informed consent was not required.
A retrospective chart review was performed on all
pediatric endocrine charts from both clinics collected
over the past 50 years. Subjects with CAH due to 21-
hydroxylase deficiency were identified from each institu-
tion and reviewed (105 in total). Gestational age
(weeks), birth weight (kg), birth length (cm) and paren-
tal heights (cm) were obtained when documented in the
chart. Subjects of gestational age < 37 weeks or > 44
weeks were omitted from the analyses. A single instance
of twin gestation was identified in our data, but was
excluded from the current analyses based on delivery at
34 weeks gestational age.
Birth weight and length information were entered into
as o f t w a r ep r o g r a m( E p iI n f o ™. version 3.4.1; 1. Epi
Info™; http://www.cdc.gov/epiinfo), yielding birth
weight, length, and weight, for, height percentiles and z-
scores. MPH was calculated based on the formula:
(maternal height (cm) ± paternal height (cm) ± 13 cm
(+13 cm for males and -13 cm for females) [23].
Wilcoxon signed-rank tests were used to test whether
birth weight and length percentiles differed from the
standard median (50th percentile), and the Mann-Whit-
ney U-test and Student t-test were used to examine the
difference in study variables between male and female
subjects with CAH. Spearman correlation coefficients
were also calculated to determine the strength of the
relationship between MPH and both birth weight (kg)
and birth length (cm).
Results
Of the 105 subjects, 91% were born between 37 and 40
weeks. Gestational age ranged from 37 to 43 weeks
(mean ± SD 39.91 ± 1.04). Mean birth weight for CAH
subjects was 3.42 kg, with an average female and male
weight of 3.39 and 3.50 kg, respectively (Table 1). No
sex difference in weight was seen (t (103) =- 1 . 1 8 ,P >
0.05). Mean birth weight percentile for CAH was
49.26%, indicating no difference in birth weight from
the expected standard population median of 50th per-
centile (S = -117, P > 0.05). There was no sex difference
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subjects (U = 1453, P > 0.05).
Of the 105 subjects with CAH, 44 (42%; 34 females
and 10 males) had birth length and gestational age
recorded in their chart (Table 2). Mean birth length for
the group of subjects was 50.90 cm, with average female
and male length of 50.79 and 51.30 cm, respectively.
There was no sex difference in birth length (U =2 3 7 ,P
> 0.05). The mean birth length percentile for all subjects
was 63.11%, which differed from the expected standard
population median of the 50th percentile (S = 221, P =
0.0082). In total, 68 subjects had their MPH calculated,
but only 30 subjects had four data points available
(gestational age, birth weight and length and MPH) to
analyze. There was no significant correlation between
birth weight (r =0 . 1 3 ,P >0 . 0 5 )o rl e n g t h( r =0 . 1 5 ,P >
0.05) percentiles and MPH.
Discussion
The sex ratio at birth in CAH, an autosomal recessive
disorder, is almost equal [24]. Female newborns are
detected more readily at birth because ambiguity of
their external genitalia resulting from excess androgen
exposure in utero [25]. Before the advent of newborn
screening for CAH due to 21-OH deficiency, male new-
borns with CAH had delayed or missed diagnoses,
resulting in salt-wasting adrenal crises and increased
mortality rates [26-29]. Thus, the 2.5:1 female:male ratio
for CAH in our data reflects the retrospective nature of
the cases that presented prior to the 1970s.
Consistent with results from previous investigations
[20], infants in the current study had birth weights in
the expected population distribution median; however,
birth length percentile was higher than the expected
population distribution median [22]. Measuring birth
length can be difficult. The neonatal cranial molding
necessary during delivery, timing after delivery, and flex-
ion of the infant’s body are a;; factors that contribute to
this difficulty [30]. However, studies report intra- and
inter-examiner reliability of birth length measurement of
>1.0 cm [31,32]. This exceeds the 7 mm intra- and
inter-examiner reliability allowed during the standardi-
zation process for the World Health Organization Child
Growth Standard curves [33]. Furthermore, our results
are consistent with those of Bonfig et al.[ 2 2 ] ,w h o
reported results from a prospective study of 51 patients.
F o ra l lt h e s er e a s o n s ,w ec o n c l u d et h a tu n l i k et h e
retarded growth pattern reported in cases of idiopathic
DSD in genetic males, birth weight and length are not
inhibited by CAH due to 21-OH deficiency.
In addition to increased birth length seen in the study
cohort overall, we failed to detect the expected sex dif-
ference in favor of birth length for male infants in our
investigation. We speculate that this is due to increased
linear growth of both females and males with classic
CAH resulting from increased levels of adrenal andro-
gens before birth. Androgens were increased for all new-
borns in this cohort, as no mothers received
dexamethasone treatment during pregnancy and all
females had ambiguous genitalia at birth.
Previous work by our group has shown that sex differ-
ences in body mass and composition in infants disap-
pear by 6 months of age, when the testes of healthy
males stop producing androgens. Further support for
our proposition that early androgen exposure drives sex
differences, at least in part, is our observation that new-
borns with 46,XY DSD due to complete androgen insen-
sitivity syndrome have birth weights that do not differ
from unaffected female newborns [34]. Taken together,
these observations strongly suggest that prenatal andro-
gen exposure, rather than the possession of a male chro-
mosome complement, stimulates linear growth and body
composition in humans in a male-typical manner.
Athough evidence from multiple sources points to the
role of androgens in prenatal growth, androgens are not
alone sufficient for normal intrauterine growth. Several
other factors are required, including the insulin-like growth
factor (IGF) system, adequate nutrient and oxygen supply
to the fetus, and normal imprinting of genes involved in
early growth. For example, children with IGF-1 deficiency
have depressed patterns of prenatal growth despite their
exposure to typical levels of androgens during gestation
[35]. Additionally, boys with Russell-Silver syndrome
experience intrauterine growth retardation and hypospa-
dias despite normal early androgen production [36].
Table 1 Birth weight and z-scores for subjects with congenital adrenal hyperplasiadue to 21-OH deficiency.
Female (n = 78) (mean ± SD) Male (n = 27) (mean ± SD) Total (n = 105) (mean ± SD)
Birth weight
1 (kg) 3.39 ± 0.47 3.50 ± 0.41 3.42 ± 0.45
z-score 0.01 ± 0.97 -0.01 ± 0.77 0.00 ± 0.92
1Mean birth weight percentile did not differ from the 50th percentile (P > 0.05) and no sex difference was seen (P > 0.05).
Table 2 Birth length and z-scores for subjects with
congenital adrenal hyperplasia due to 21-OH deficiency.
Parameter Results, mean ± SD
Female (n = 34) Male (n = 10) Total (n = 44)
Birth length (cm)
1 50.79 ± 2.65 51.30 ± 3.64 50.90 ± 2.86
z-Score 0.53 ± 0.99 0.51 ± 1.39 0.53 ± 1.07
1Mean birth length percentile exceeded the population 50th percentile (P =
0.0082) and no sex difference was seen (P > 0.05).
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increased birth length could be due to a relative defi-
ciency of cortisol, which has well-known growth-sup-
pressing effects, or to excess levels of adrenal hormone
precursors in utero, including 17-hydroxyprogesterone.
Studies of non-human animal models indicate that
maternal activation of the hypothalamic-pituitary-adre-
nal axis during pregnancy results in alterations in off-
spring body mass, but not skeletal growth [37-39].
Conversely, non-human animals hypophysectomized in
utero have reduced body mass [40], limb length [41,42]
and crown rump length [42], the opposite outcome of
the increased birth length seen in the current study.
It seems that newborns with CAH have already
experienced some alterations in linear growth compared
with their unaffected counterparts. Possibly, some of the
difficulty seen in effecting normal linear growth
throughout childhood of individuals with this disorder
may be independent of post-natal cortisol-replacement
regimens.
Conclusion
The prenatal growth retardation patterns reported in
c a s e so f4 6 , X YD S Dd on o tg e n e r a l i z et oi n d i v i d u a l s
with CAH due to 21-OH deficiency. Sex differences in
body weight and length typically seen in young infants
were not observed in the subjects who participated in
this study. We speculate that these differences were
ameliorated in this study due to increased levels of pre-
natal androgens experienced by the female infants.
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